CAPRICOR THERAPEUTICS, INC.

Capricor Therapeutics is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare and serious diseases with limited treatment options. The company's lead candidate, Deramiocel, is an allogeneic cardiosphere-derived cell therapy currently in phase 3 clinical trials for Duchenne muscular dystrophy (DMD). Beyond its primary DMD program, Capricor is advancing a pipeline of exosome-based candidates, including StealthX, an engineered exosome vaccine platform in phase 1 development for multiple therapeutic applications involving targeted RNA, protein, and small molecule delivery. The company also maintains preclinical programs for exosome-based approaches to treat COVID-19 and additional DMD-related indications.

The company operates through partnerships and licensing agreements with academic and medical institutions, including Johns Hopkins University, the University of Rome, and Cedars-Sinai Medical Center, which provide access to proprietary cell lines and intellectual property for therapeutic development. Revenue generation remains limited given the clinical-stage nature of the business, with commercialization potential dependent on successful advancement of pipeline candidates through regulatory approval.

Capricor is headquartered in San Diego, California, with approximately 160 full-time employees. The company is incorporated in Delaware and listed on the Nasdaq exchange.